MINNEAPOLIS & CHICAGO--(BUSINESS WIRE)--As ACC.08, the annual congress of the American College of Cardiology nears its close, Medtronic Inc. (NYSE: MDT - News) reaffirms its commitment to clinical evidence supporting the full range of implantable cardiac device therapy as standard of care for patients with heart failure, arrhythmias and those at risk of sudden cardiac arrest (SCA). As evidenced by today’s Late Breaking Scientific Sessions on three Medtronic-sponsored clinical trials, and poster data presented earlier in the congress, Medtronic continues to advance clinical science that impacts medical practice worldwide.
